Pharmaceutical giants Eli Lilly and Novo Nordisk are two dividend stocks that are worth considering for investors. Despite their premium valuations, both companies have shown impressive returns and have promising growth prospects. Eli Lilly has generated excitement with its groundbreaking treatments for Alzheimer’s disease and obesity, propelling its stock to new heights. The company has a robust product portfolio and clinical pipeline that can sustain its momentum, making it an attractive choice for growth and income investors. Although its dividend yield is modest, Lilly’s dividend is considered safe with a reasonable payout ratio and an expected rise in its top line.
Novo Nordisk, a global leader in diabetes and obesity, has consistently grown its revenues and profits, thanks to its focus on innovation and expansion into emerging markets. The company’s stock has performed exceptionally well, outpacing the S&P 500 index. While its dividend yield is not particularly high, Novo Nordisk’s low payout ratio and anticipated double-digit revenue growth suggest that its dividend program is sustainable in the long run.
Overall, both Eli Lilly and Novo Nordisk are high-quality companies that offer the potential for consistent and growing dividends. Despite their premium valuations, their impressive returns and promising growth prospects make them strong buys for investors seeking dividend stocks to boost their portfolio returns.
